Navigation Links
Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/22/2007

s to Subjects with Severe Renal Impairment"

Cethromycin at 300 mg QD for five days was well tolerated by both subjects with severe renal impairment and with normal renal function. Elevated drug exposure observed for subjects with severe renal impairment suggest that these patients should be monitored when taking cethromycin.

The following poster presentations discussed cethromycin as a potential treatment for CAP, particularly when resistance to other treatments is known:

"Assessment of In Vitro Activity of Cethromycin Against Telithromycin-resistant Strains of Streptococcus Pneumoniae"

All eight clinical Streptococcus pneumoniae isolates were resistant to erythromycin with MICs > 128 micron g/mL and had telithromycin MICs >/= 2 micron g/mL. For six of these isolates, the cethromycin MIC was at least 8-fold lower than the telithromycin MIC, for another isolate the MICs were the same, and for the other the telithromycin MIC was one doubling dilution lower than the cethromycin MIC.

Cethromycin maintained good in vitro potency against a collection of telithromycin-resistant S. pneumoniae isolates. This finding suggests that underlying resistance mechanisms that result in reduced telithromycin susceptibility do not affect cethromycin to the same extent. Therefore, cethromycin continues to represent a reasonable potential therapeutic option for S. pneumoniae of this phenotype.

"Assessment of In Vitro Activity of Cethromycin Against Strains of Streptococcus Pneumoniae"

Cethromycin demonstrated potent in vitro activity against all Streptococcus pneumoniae populations studied, regardless of their resistance phenotype. Based on MIC90 data collected, cethromycin was 2-4 times more potent than telithromycin and 10-12 times more potent than the macrolides studied. These findings demonstrate that cethromycin has the potential to be a potent therapeutic option for the treatment of CAP, even for infections caused by strains resistant to cu
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Managing Preanalytical Processes for Patient Safety
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... ROCKVILLE, Md. , May 20, 2013  Neuralstem, ... Eva Feldman , MD, PhD, principal investigator, presented ... neural stem cell (NSI-566) trial in the treatment of ... ,s disease) at the neuro diabetes special medical ... Friday. In a talk called "Recent Therapeutic Advances in ...
(Date:5/20/2013)... , May 20, 2013 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that ... offering a greater effect on quality of life ... Given the high level of subjectivity and variability ... interviewed thought leaders state that it is difficult ...
(Date:5/19/2013)... 20, 2013  Whole-cell pertussis vaccines were more effective ... a large recent outbreak, according to a new Kaiser ... vaccines, also called DTwP, were available from the 1940s ... ultimately led to the development of acellular pertussis vaccines, ... the United States had switched ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4
... , , TITUSVILLE, ... U.S. Food and Drug Administration approved INVEGA(R) SUSTENNA(TM) (paliperidone ... treatment of schizophrenia in adults on Friday, July 31, ... antipsychotic approved in the U.S. for this use. Janssen((R)), ...
... NEW YORK, July 29 Grammy-Award winning artist and ... to create an exclusive (RED)ZONE seating section for his August 13th, ... Beginning July 29th, every purchase at select Gap stores in the ... shoppers to obtain one ticket in the reserved RED(ZONE) section for ...
Cached Medicine Technology:Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 2Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 3Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 4Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 5Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 6Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 7Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 8Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 9John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden 2John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden 3
(Date:5/20/2013)... This summer, digital health leaders from across ... pilgrimage to San Diego, CA, the emerging digital health ... Summit produced by Living in Digital Times. ... the latest digital health innovations, exchange new information, share ... of industry’s most brilliant thinkers and doers, while elevating ...
(Date:5/20/2013)... By Dennis Thompson HealthDay Reporter , , MONDAY, ... with attention deficit-hyperactivity disorder (ADHD) are twice as likely ... the disorder when they were young, a new 30-year ... ADHD tended to have a higher body-mass index (BMI) ... of the disorder. Socioeconomics made no difference; well-off ...
(Date:5/20/2013)... subdural hematoma (PFSDH) is a serious and rare condition ... appropriate treatment, there,s an excellent chance of good long-term ... study in the May issue of Neurosurgery ... Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , The results support an ...
(Date:5/20/2013)... Philadelphia, PA (May 21, 2013) Wolters ... its Lippincott Williams & Wilkins (LWW) published journals ... annual awards competition recognizes member articles and publications ... , "It,s a tremendous honor to be recognized ... have become synonymous in the industry with quality, ...
(Date:5/20/2013)... Today, Allayo announced the debut of their ... application called Allie helps health care consumers who are ... arrange for quality health care. Ideal for busy individuals ... technology and access to personalized service from certified medical ... care needs are being met. Allie is being previewed ...
Breaking Medicine News(10 mins):Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 3Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2Health News:Allayo Debuts Virtual Health Assistant At HealthBeat 2013 2
... application remains elusive, expert says , , WEDNESDAY, Feb. 25 ... of scientists has created two chemical compounds that appear ... a lack of oxygen. , "It is known that ... brain, which can be produced during hypoxia, it leads ...
... Chairman; Siegrist Takes on Executive PostSOUTH BEND, Ind., Feb. 25 ... transition from president and chief executive officer to chairman of ... Rick Siegrist, M.B.A., president of a Press Ganey subsidiary, PatientFlow ... Ganey Board of Directors, will take on the top executive ...
... White House to ,Protect the Safety Net, , WASHINGTON, ... two leading long-term care advocacy organizations, the American Health ... Home Care, today praised and thanked U.S. Representatives Earl ... and Ginny Brown-Waite (R-FL) for sending a new letter ...
... Laboratories(TM), a division of Ben Venue Laboratories, Inc., today ... product is AP rated and is equivalent to Imitrex(R) ... indicated for 1) the acute treatment of migraine attacks ... of cluster headache episodes. Sumatriptan Succinate Injection is not ...
... NEW YORK, February 25, 2009 The National ... awarded The City College of New York (CCNY) ... million grant to implement a unique partnership in ... award is funded by NCI,s U54 program, an ...
... COLORADO SPRINGS, Colo., Feb. 25 /PRNewswire/ -- ... the National Academy of Sciences, (NAS) report. Recognizing ... NAS report provides insight toward the path forward. ... improve and enhance the forensic sciences have been propounded, ...
Cached Medicine News:Health News:Compounds Found to Protect Rabbits From Cerebral Palsy 2Health News:Changing of the Guard at Press Ganey 2Health News:Changing of the Guard at Press Ganey 3Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 2Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 3Health News:Bedford Laboratories(TM) to Begin Shipping Sumatriptan Succinate Injection 2Health News:NIH awards $15.9 million to CCNY and Memorial Sloan-Kettering to create partnership 2
The Stat Profile pHOx CO-Oximeter is intended for use in those situations where a more comprehensive profile beyond the measured hematocrit, hemoglobin, and SO2% offered by the Stat Profile pHOx ...
Maxi-Therm® hyper-hypothermia water blankets from Cincinnati Sub-Zero are designed for single-patient use. These blankets are easy to clean, stain resistant and ideal for isolation cases....
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Oximetry Data Management Program is a ... with the FingerPrint® Sleep Hand-Held Pulse ... PM, Inc. catalog #3389 Interface Cable, ... sleep screening, oxygen therapy validation, and/or ...
Medicine Products: